The recombinant human granulocyte colony stimulating factor (G-CSF) product, filgrastim, and the related pegylated molecule, pegfilgrastim, have been licensed for the prevention of chemotherapy-induced neutropenia and its life-threatening complications. Here, CSF3 is linked to neutropenia.